CA2867701C - Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles - Google Patents

Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles Download PDF

Info

Publication number
CA2867701C
CA2867701C CA2867701A CA2867701A CA2867701C CA 2867701 C CA2867701 C CA 2867701C CA 2867701 A CA2867701 A CA 2867701A CA 2867701 A CA2867701 A CA 2867701A CA 2867701 C CA2867701 C CA 2867701C
Authority
CA
Canada
Prior art keywords
particles
dtpa
composition
less
zinc acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2867701A
Other languages
English (en)
French (fr)
Other versions
CA2867701A1 (en
Inventor
James David Talton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ology Bioservices Inc
Original Assignee
Nanotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanotherapeutics Inc filed Critical Nanotherapeutics Inc
Publication of CA2867701A1 publication Critical patent/CA2867701A1/en
Application granted granted Critical
Publication of CA2867701C publication Critical patent/CA2867701C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2867701A 2012-03-22 2013-03-14 Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles Active CA2867701C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261614333P 2012-03-22 2012-03-22
US61/614,333 2012-03-22
US201361771873P 2013-03-03 2013-03-03
US61/771,873 2013-03-03
PCT/US2013/031336 WO2013142258A1 (en) 2012-03-22 2013-03-14 Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

Publications (2)

Publication Number Publication Date
CA2867701A1 CA2867701A1 (en) 2013-09-26
CA2867701C true CA2867701C (en) 2020-10-27

Family

ID=48014341

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2867701A Active CA2867701C (en) 2012-03-22 2013-03-14 Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles

Country Status (8)

Country Link
US (1) US9040091B2 (https=)
EP (1) EP2827853A1 (https=)
JP (1) JP2015510935A (https=)
KR (1) KR20140139563A (https=)
AU (1) AU2013235491A1 (https=)
CA (1) CA2867701C (https=)
MX (1) MX2014011123A (https=)
WO (1) WO2013142258A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939760C (en) * 2014-02-18 2022-05-31 Medesis Pharma Use of a reverse-micellar system for delivering chelators of radionuclides and metals
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
JP2018052884A (ja) * 2016-09-29 2018-04-05 菊川　正 放射線核種キレート化剤を内包する経口投与剤
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
EP4719356A1 (en) 2023-06-05 2026-04-08 Nanopharmaceutics, Inc. Compositions and methods for oral delivery of sustained release crystalline prx-3140

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
US7910086B1 (en) * 2005-01-04 2011-03-22 Gp Medical, Inc. Nanoparticles for protein drug delivery
JP2009500163A (ja) * 2005-07-07 2009-01-08 ナノセラピューティクス・インコーポレイテッド 粉末を製粉および調製する方法及びそれにより得られる組成物
JP4975047B2 (ja) * 2006-02-17 2012-07-11 エスアールアイ インターナショナル 放射性核種のキレート化のための経口ｄｔｐａ
WO2011133198A1 (en) * 2010-04-21 2011-10-27 Hosheng Tu A pharmaceutical composition of nanoparticles

Also Published As

Publication number Publication date
MX2014011123A (es) 2014-12-05
KR20140139563A (ko) 2014-12-05
EP2827853A1 (en) 2015-01-28
US20130251815A1 (en) 2013-09-26
CA2867701A1 (en) 2013-09-26
AU2013235491A1 (en) 2014-09-11
JP2015510935A (ja) 2015-04-13
US9040091B2 (en) 2015-05-26
WO2013142258A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
US11071740B2 (en) Method of treatment using nanoparticulate ganaxolone formulations
ES2739888T3 (es) Composiciones y comprimidos farmacéuticos con recubrimiento compresible y métodos de fabricación
AU2007260822B2 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
CA2867701C (en) Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
DE60010464T2 (de) Geschmackskaschierte flüssige arzneizubereitungen
JP2002080398A (ja) ｐＨに依存する多相的な放出を伴う経口用の固体の薬学的組成物
CN101484170A (zh) 包含纳米颗粒萘普生和控释氢可酮的组合物
ES2584403T3 (es) Procedimiento de elaboración de microcápsulas entéricas de alginato por gelación iónica que contienen diclofenac o una de sus sales y composición farmacéutica multiparticulada que las contiene
DE69914360T2 (de) Chromone zubereitung zur enteralen wirkstofffreisetzung
CN107595794A (zh) 一种盐酸克林霉素棕榈酸酯颗粒及其制备方法
JP2008525389A (ja) 活性成分移送のための新規ガレン製剤系、その製造方法および用途
WO2022072099A9 (en) Immediate release dosage forms, methods of making and using
BR112019016400A2 (pt) composições de complexos de gálio (iii) para administração oral
CN120959403A (zh) 一种肠溶纳米晶组合物的制备方法
HK40119254A (zh) 包含去铁酮的调释药物制剂
MXPA06010047A (es) Preparacion farmaceutica solida que contiene farmaco escasamente soluble en agua.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180228

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241214

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202